Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

此前，瓯江实验室首席科学家李校堃、资深研究员穆萨·穆罕默迪、特聘研究员陈高帜团队共同在《自然》杂志发表文章《FGF激素信号传导的结构基础》，其研究便是通过冷冻电镜完成。该文章在国际上首次完整展示FGF23、FGFR、Klotho和HS四元复合物分子机 ...

University of Auckland senior research fellow Jeff Smaill first visited China in 2012 as part of a team of 15 scientists from the Maurice Wilkins Center, one of New Zealand’s centers of excellence, to ...

A new targeted therapy aimed specifically at FGFR3, TYRA-300, is showing preliminary promise in patients with advanced FGFR3-altered bladder cancer.Partial responses have been seen in an ongoing phase ...

Leerink Partners analyst Mani Foroohar maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) on November 12 and set a ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical ...

Despite an outcome that TD Cowen analyst Tyler Van Buren called ”fantastic,” shares of Tyra Biosciences Inc. (NASDAQ:TYRA) closed Oct. 25 at $21.93, down $6.68, or 23%, as Wall Street digested new ...

Please note that following on from information provided to NICE by the company in January 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from ...

This work is an important contribution to understanding the role of FGF signaling in the induction of primitive-like cells in a 2D system of human gastrulation. The authors provide compelling evidence ...

Multi-kinase inhibition by fexagratinib may offer a more comprehensive therapeutic approach than selective FGFR inhibition in ...

Tyra Bioscience, Inc ( (TYRA) ) has released its Q3 earnings. Here is a breakdown of the information Tyra Bioscience, Inc presented to its ...